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Purpose: To investigate the role of mast cells and annexin-A1 (Anxa1) in endotoxin-induced uveitis (EIU).
Methods: EIU was induced by injection of lipopolysaccharide (LPS) into the paws of rats, which were then sacrificed
after 24 and 48 h. To assess EIU in the absence of mast cells, groups of animals were pretreated with compound 48/80
(c48/80) and sacrificed after 24 h after no treatment or EIU induction. The eyes were used for histological studies and the
aqueous humor (AqH) pool was used for the analysis of transmigrated cells and Anxa1 levels. In inflammatory cells,
Anxa1 expression was monitored by immunohistochemistry.
Results: After 24 h, rats with EIU exhibited degranulated mast cells, associated with elevated numbers of infiltrating
leukocytes and the high expression of Anxa1 in the AqH and the neutrophils. After 48 h of EIU, the mast cells were intact,
indicating granule re-synthesis, and there was a reduction of neutrophil transmigration and an increase in the number of
mononuclear  phagocytic  cells  in  ocular  tissues.  Anxa1  expression  was  decreased  in  neutrophils  but  increased  in
mononuclear phagocytic cells. In the animals pretreated with c48/80 and subjected to EIU, mast cells responded to this
secretagogue by degranulating and few transmigrated neutrophils were observed.
Conclustions: We report that mast cells are a potential source of pharmacological mediators that are strongly linked to
the pathophysiology of EIU, and the endogenous protein Anxa1 is a mediator in the homeostasis of the inflammatory
process with anti-migratory effects on leukocytes, which supports further studies of this protein as an innovative therapy
for uveitis.
Uveitis is a harmful inflammatory ocular condition that
can be caused by infections and autoimmune diseases [1-3].
Although inflammation resolves in a few days, the recurrent
nature  of  uveitis  may  result  in  other  sight-threatening
conditions such, as cataracts, glaucoma and even blindness
[4,5].
Endotoxin-induced uveitis (EIU) is a widely accepted
animal  model  for  the  study  of  acute  ocular  inflammation
[6-8]. EIU is generally considered to be an inflammation of
the anterior uvea, with some changes in the posterior segment
(vitreous and retina) [9,10]. Exposure to exogenous bacterial
toxins, such as lipopolyssacaride (LPS), stimulates ocular-
resident cells to produce inflammatory cytokines, such as
tumor  necrosis  factor  (TNF)-α  and  other  cytokines  and
inflammatory mediators [7,11].
Increased expression of inflammatory mediators leads to
an infiltration of leukocytes that amplifies the inflammatory
reaction  in  the  eye  [7,12].  Many  of  these  inflammatory
mediators are released by mast cells [13], which are highly
specialized secretory cells, that play roles in both the innate
and adaptive immune responses [14,15].
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The major pathway for the activation of mast cells is the
signaling cascade caused by the aggregation of high affinity
receptors (FceRI) for immunoglobulin E (IgE), due to the
binding  of  specific  antigens  [15].  An  alternative  way  of
activating mast cells is through exposure to a large number of
polycationic  molecules  collectively  known  as  the  basic
secretagogues  of  mast  cells,  such  as  synthetic  compound
48/80 (c48/80) [16,17]. These agonists act as receptor mimetic
agents  that  trigger  mast  cell  degranulation  by  directly
activating  pertussis  toxin  (Ptx)-sensitive  guanosine
triphosphate  inhibitory  binding  (Gi)  proteins  that  control
exocytosis [18-20].
Due  to  the  fact  that  mast  cells  are  essential  for  the
resolution  of  bacterial  infections  through  neutrophil
mobilization to the site of infection [14], it has been suggested
that their degranulation may contribute to the inflammatory
process of EIU [21]. One of the endogenous mediators present
in these mast cell granules is the protein Annexin A1 (Anxa1)
[22].
Anxa1 is a member of a superfamily of annexin proteins
that  bind  acidic  phospholipids  with  high  affinity  in  the
presence  of  Ca2+  [23].  The  interest  in  this  protein  has
dramatically increased due to its potent anti-inflammatory and
immunomodulatory  properties  [24].  In  this  regard,  this
endogenous mediator regulates acute [25] and chronic [22]
inflammation.  Anxa1  is  a  ubiquitous  protein,  and  many
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1310inflammatory cells, in addition to mast cells, express this
mediator,  such  as  neutrophils  [26],  eosinophils  [27],
monocytes [28], and T cells [29].
This study indicates that mast cells are a potential source
of pharmacological mediators that are, strongly linked to the
pathophysiology  of  EIU.  Additionally,  this  investigation
indicates that the endogenous protein Anxa1 is a mediator in
the  homeostasis  of  the  inflammatory  process  because  it
exhibits  anti-migratory  effects  on  leukocytes.  The  results
indicate the requirement for further studies of this protein as
an innovative therapy for uveitis.
METHODS
Animals and endotoxin induced uveitis (EIU): Male Wistar
rats (São José do Rio Preto Medical School, São Paulo, Brazil)
weighing 150-200 g (6 weeks old) were randomly distributed
into 5 groups (n=10). The animals were housed in a 12 h light-
dark cycle and were allowed food and water ad libitum. EIU
was induced by a single subcutaneous injection of 0.2 mg
Escherichia coli LPS endotoxin (Sigma Chemical Co. Poole,
Dorset, UK) in 0.1 ml PBS into one hind footpad and the rats
were euthanized at 24 h or 48 h after LPS injection. Control
rats were injected with 0.1 ml PBS into the hind footpad.
Compound 48/80 (c48/80) treatment: To further analyze the
role played by mast cells in EIU, two groups of rats were
treated with increasing doses of c48/80 (from 0.2 mg to 1 mg
in 0.5 ml of PBS). The compound was administered twice
daily, intraperitoneally, over 5 days. Then, one group of rats
was  treated  to  induce  EIU  and  both  groups  of  rats  were
euthanized after 24 h. All of the experiments were conducted
in  compliance  with  the  ARVO  Statement  for  the  Use  of
Animal in Ophthalmic and Vision Research. The study was
approved  by  the  Ethics  Committee  in  Animal
Experimentation of the Federal University of São Paulo (São
Paulo, Brazil; No. 0061/06).
Histopathological evaluation: The right eyes of the rats were
enucleated  and  fixed  in  a  PBS  solution  containing  4%
paraformaldehyde and 0.5% glutaraldehyde for 24 h at 4 °C,
dehydrated by graded methanol and embedded in LRGold
resin (London Resin Co., Reading, Berkshire, UK). Tissue
sections (1 µm) were stained with toluidine blue. Infiltrating
inflammatory cells in the anterior and posterior segments were
evaluated by visual inspection in a blind fashion and counted
with a high-power objective (40×) on an Axioskop 2-Mot Plus
Zeiss microscope (Carl Zeiss, Jena, Germany). The mast cells,
neutrophils and mononuclear phagocytes were distinguished
by  their  specific  morphological  characteristics,  including
metachromatic cytoplasmic granules of mast cells and the
nuclei  of  the  leukocytes.  The  number  of  infiltrating
inflammatory cells in 10 sections per eye, from five eyes from
different animals, was averaged and recorded. Values were
reported as the mean±SEM of number of cells-per-mm2.
Infiltrating cells and total proteins concentration in AqH:
Aqueous humor (AqH) was collected from the left eyes by
anterior chamber puncture using a 29-gauge needle. The AqH
pool  was  centrifuged  and  protein  concentration  in  the
supernatant was measured using a Bradford assay (Biorad,
Hemel  Hempsted,  UK).  For  cell  counting,  the  pellet  was
resuspended in PBS, and aliquots (100 µl) were diluted in
Turk stain solution (1:10). The cells were counted with a
Neubauer  chamber  (Laboroptik  GmbH,  Friedrichsdorf,
Hessen, Germany) under a light microscope.
Immunohistochemical  studies:  To  detect  Anxa1  protein
expression, the eye sections (1 μm thick) were incubated with
the following reagents at room temperature: Tris buffer 0.1
M, pH 5.4 (TBS) for 30 min; 3% hydrogen peroxide for 30
min and; 0.1% Tween-20 (Sigma-Aldrich Poole, Dorset, UK)
diluted in TBS for 15 min. Non-specific binding sites were
blocked with 10% BSA diluted in TBS (20 mM Tris buffer in
0.9% NaCl, pH 8.2) for 30 min. Sections were incubated
overnight  with  a  primary  polyclonal  rabbit  anti-Anxa1
antibody (1:200; Zymed Laboratories, Cambridge, UK). After
repeated washings in 1% PBS, a goat anti-rabbit IgG (Fc
fragment-specific) antibody conjugated to 5 nm colloidal gold
(1:50; British BioCell International, Cardiff, UK) was added.
Silver enhancing solution (British BioCell International) was
used  to  augment  gold  particle  staining  followed  by
hematoxylin counterstaining. Analysis was conducted with a
Axioskop 2-Mot Plus Zeiss microscope (Carl Zeiss), using the
AxioVision software (Zeiss).
Western blotting analysis: AqH was sonicated in Tris-HCl
solution (50 mM) containing phenylmethylsulphonilfluoride
(1  mM,  pH  7.4).  The  protein  levels  were  determined  by
Bradford assay (Biorad, Hemel Hempsted, UK) and equalized
before boiling in Laemmli buffer (4% SDS, 20% glycerol,
1 mM DTT, 2 mM EDTA and 1 mg/ml Coomassie brilliant
blue). Equal amounts of protein (25 μg) were loaded onto a
10%  sodium  dodecyl  sulfate-polyacrylamide  gel  for
electrophoresis  together  with  the  appropriate  molecular
weight  markers  (Amersham  Pharmacia  Biotech,
Buckinghamshire,  UK)  and  transferred  onto  a  Hybond-C
extra nitrocellulose membrane (Amersham, Little Chalfont,
UK). Membranes were blocked for 1 h with 5% non-fat dry
milk diluted in TBS with 0.1% Tween-20 (TBST). Anxa1
expression was detected by an overnight incubation with the
rabbit polyclonal Anxa1 antibody (1:1,000; Zymed). Equal
loading  was  confirmed  with  an  anti-α-tubulin  antibody
(1:2,000; Santa Cruz Biotechonology, Santa Cruz, CA). In
both  cases,  the  signal  was  amplified  with  peroxidase-
conjugated goat anti-rabbit IgG (1:2,000; Serotec, Oxford,
UK)  diluted  in  TBST  and  visualized  with  an  enhanced
chemiluminescence  kit  (Amersham,  Little  Chalfont,  UK).
Then,  densitometry  was  performed  by  the  image  analysis
system (AxioVision Software; Zeiss).
Statistical analysis: All data are the mean±SEM of n≥5 rats
per group. Statistical differences between the means were
determined by analysis of variance (ANOVA) followed, and
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value of less than 0.05 was considered significant.
RESULTS
Analysis  of  inflammatory  cells  in  ocular  tissues  in  EIU:
Initially, typical mast cells with intact granules were identified
after staining with toluidine blue. In the control group, intact
mast cells were observed mainly in the posterior eye segment
(Table 1). Analysis 24 h after endotoxin injection showed a
significant increase in the number of mast cells compared to
the control group. These cells were observed in the process of
degranulation  in  the  ciliary  body  (100%;  Figure  1C)  and
choroid (53%). In the later phase of inflammation at 48 h post-
injection,  a  decrease  of  approximately  50%  of  the  total
number of mast cells was observed when compared to the
group assessed after 24 h. All of the mast cells observed in the
anterior (Figure 1E) and posterior eye segments were found
to be intact. Mast cells were completely absent in the ocular
tissues of all animals that received pretreatment with c48/80
(Figure 1G). The quantitative analyses of the mast cells in the
eye are reported in Table 1.
Histopathological and quantitative analyses revealed a
large increase in the transmigration of inflammatory cells into
the eye, mainly into the anterior segment, when assessed 24 h
after  LPS  injection  (Figure  1D;  Table  2),  whereas  no
infiltrating cells were observed in the eyes of control animals
(Figure 1A,B; Table 2). Although the inflammatory process
induced by LPS was most evident in the anterior eye segment,
we observed changes in the posterior segment, including a
significant increase of neutrophils in the choroid (p<0.001)
and the retina (p<0.01; Table 3). In the late inflammatory
response at 48 h post-injection, the number of neutrophils
decreased significantly in the iris, ciliary body and choroid-
retina complex (p<0.001; Table 2 and Table 3). However, a
significant  increase  of  mononuclear  phagocytic  cells  was
observed, and these cells were mainly adhered to the iris
(Figure 1F; Table 2 and Table 3).
The number of transmigrated leukocytes in the anterior
and  posterior  segments  at  24  h  was  significantly  lower
(p<0.001) in EIU animals pretreated with c48/80 and given
LPS injection, compared to animals that had induced uveitis
without pre-treatment (Figure 1H; Table 2 and Table 3). In the
ocular  tissues  of  animals  only  pretreated  with  the
secretagogue, there were no inflammatory cells (Table 2 and
Table 3).
Analysis of the AqH in EIU:
Total  cell  count—An  influx  of  neutrophils
(18±2.0×103  cells/μl)  and  mononuclear  phagocytic  cells
(14±1.5×103 cells/μl) was observed in the AqH of the animals
at 24 h after EIU. In the late inflammatory process, there was
a reduction in the number of neutrophils (15±0.5×103 cells/
μl),  whereas  mononuclear  phagocytic  cells  increased
(35±2.2×103 cells/μl) when compared to the initial phase.
However, leucopenia was observed in the AqH of animals
pretreated with c48/80, with or without the induction of uveitis
(5±0.5×103 cells/μl; Figure 2A).
Total proteins—Total proteins levels were evaluated at
24 and 48 h after endotoxin injection. At both 24 and 48 h,
groups with EIU exhibited significantly higher protein levels
(590±10 and 600±20 mg/ml, respectively) when compared
with the control group (100±10). In the groups pretreated with
c48/80,  the  protein  levels  were  lower  than  in  the  initial
inflammatory process at 24 h (350±20; Figure 2B).
Anti-inflammatory  protein  Annexin-A1:  Western  blotting
analysis  of  the  AqH  detected  Anxa1  in  all  experimental
groups.  However,  in  animals  pretreated  with  c48/80  and
evaluated  24  h  after  uveitis  induction,  an  increased
immunoreactivity for Anxa1 was detected when compared
with other experimental groups (Figure 2C).
Annexin-A1 expression in inflammatory cells in EIU: Next we
analyzed  Anxa1  expression  with  a  polyclonal  anti-Anxa1
antibody  which  detects  the  intact  (37  kDa)  and  cleaved
(33  kDa)  forms  of  the  protein.  Mast  cells  were
immunoreactive for Anxa1 in ocular tissues from the control
group, and in the tissues collected 24 (Figure 3A) and 48 h
after  endotoxin  injection.  Statistical  analysis  showed  a
significant reduction in Anxa1 expression in mast cells from
the animals with EIU at 24 h (150±12) compared to control
TABLE 1. QUANTITATIVE ANALYSIS OF MAST CELLS IN THE EYE.
Groups Anterior segment Posterior segment
  Mast cells
  Intact Degranulated Intact Degranulated
Control 0.0 0.0 4.0±2 0.0
LPS 24h 0.0 15±3*** 7.0±1.5 8.0±1.0
LPS 48h 12±3††† 0.0 5.0±2.0 0.0
C48/80 0.0 0.0 0.0 0.0
C48/80 + LPS 24h 0.0 0.0 0.0 0.0
        Data are the mean±SEM of mast cells per mm2 analyzed in the ocular tissues of control animals, animals with EIU at the initial
        (LPS 24h) and late phases (LPS 48h), animals pretreated with c48/80 and animals pretreated with c48/80 and then subjected to
        endotoxemia (c48/80 + LPS24h). ***p<0.001 versus control, †††p<0.001 versus LPS 24h.
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alteration  in  the  Anxa1  expression  in  the  late  phase  of
inflammation (165±11) was observed when compared to the
initial phase (Figure 3D).
In  tests  performed  on  neutrophils  and  mononuclear
phagocytic cells, we observed immunoreactivity for Anxa1 at
24 and 48 h post-injection in the anterior (Figure 3B,C) and
posterior  eye  segments.  The  statistical  analysis  showed
significantly  higher  Anxa1  expression  in  neutrophils  and
mononuclear phagocytes at 48 h than at 24 h after uveitis
induction (Figure 3D).
DISCUSSION
Experimental uveitis is widely used as a pre-clinical model
for  predicting  drug  efficacy  in  human  settings.  The
involvement of mast cells has been evaluated in important eye
diseases, such as conjunctivitis, atopic keratoconjunctivitis,
and uveitis [30-32]. However, the role of mast cells in EIU
has not been well studied. Thus, initially we investigated mast
cells  in  rodent  eyes  to  verify  the  presence,  distribution,
characteristics  and  participation  of  these  cells  in  the
intraocular inflammation after endotoxemia. We observed the
recruitment and activation of mast cells in the experimental
animals 24 h after the injection of the inflammatory stimulus
of LPS, which coincided with the influx of leukocytes that
Figure 1. Histopathological analysis of
the anterior eye segment. A-H: Light
micrographs  of  rat  eyes  stained  with
toluidine  blue.  A,  B:  Ciliary  body  of
control animals. C: Degranulated mast
cell (curved arrow) in the ciliary body
and  extensive  inflammatory  cell
infiltration  in  AqH  (D),  mainly
neutrophils  (arrows)  at  24  h  after
endotoxin injection (LPS 24h). E: Intact
mast cell (curved arrow) in the ciliary
process  and  mononuclear  phagocytic
cells (open arrows) adhered to the iris
surface (F) at 48 h post-injection (LPS
48h). G, H: Ciliary  bodies of  animals
pretreated  with  secretagogue  c48/80
before  EIU  (c48/80  +  LPS  24h).
Absence  of  mast  cells  and  very  few
transmigrated  inflammatory  cells
(arrow). V: blood vessel. Bars, 10 μm.
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1313occurred  after  the  breakdown  of  the  blood-ocular  barrier,
particularly in the anterior eye segment.
Mast  cells  secrete  multiple  mediators,  including
histamine, heparin, serine proteases, lipid-derived mediators
and cytokines, which cause the clinical signs of inflammation
[13,33].  When  mast  cells  are  challenged  by  an  external
stimulus,  they  respond  by  degranulation  and  the  release
vasoactive  mediators  [14,20]  indicating  that  these  cells
influence the pathophysiology in experimental uveitis. The
synthesis and release of eicosanoids and cytokines by mast
cells are required for leukocyte transmigration into the site of
inflammation  [20,34-36].  In  the  late  phase  of  the
inflammatory response, 48 h after LPS administration, most
mast cells present were found to be intact suggesting that these
cells, after the initial activation, can re-synthesize the contents
of their cytoplasmatic granules. Granular content re-synthesis
after the secretion and extrusion of the cytoplasmatic granules
was also studied in mast cells isolated from human lungs
[37]. Our detailed histological analyses revealed a significant
reduction of neutrophils, in contrast to the increase of the
mononuclear phagocytic cells in ocular tissues, which was
also seen in other studies [38].
The next step of our study was to evaluate mast cells in
the  process  of  leukocyte  chemotaxis  during  ocular
inflammation. For this purpose, we depleted mast cells in the
ocular tissues by pre-treatment with the secretagogue c48/80.
This compound acts on the cell surface, directly stimulating
the activity of the GTPase associated with the membrane,
which results in an increase in intracellular calcium [20,21,
39] and in the depletion of intragranular mediators. Our results
demonstrated that ocular tissue mast cells responded to c48/80
by degranulation and correspond to the connective tissue mast
cells (CTMCs). The absence of mast cells, and thus the lack
of the chemotactic mediators during EIU in ocular tissues,
resulted  in  a  reduction  in  the  number  of  transmigrated
leukocytes, confirming the importance of these mediators in
chemotaxic  process  of  inflammatory  cells  [35,36].
Furthermore, studies have shown that mast cell depletion by
c48/80  resulted  in  a  reduced  number  of  neutrophils
transmigrated into the peritoneal cavity of rats subjected to
peritonitis [40].
Next, we analyzed the leukocytes and total protein in the
anterior  eye  chamber  after  EIU.  These  analyses  were
conducted on the AqH and indicated a high increase in the
transmigration  of  inflammatory  cells  and  the  leakage  of
plasma proteins at 24 and 48 h after EIU. In the literature, it
has  been  demonstrated  that  the  increased  vascular
permeability to plasma proteins is one of the main results of
TABLE 2. QUANTITATIVE ANALYSIS OF NEUTROPHILS AND MONONUCLEAR PHAGOCYTIC CELLS IN THE ANTERIOR EYE SEGMENT.
Groups Iris Ciliary body
  Nϕ Mϕ Nϕ Mϕ
Control 0.0 0.0 0.0 0.0
LPS 24h 150±10*** 25±5.0*** 182±23*** 0.0
LPS 48h 12±3.0††† 154±12††† 17±3.0††† 91±13†††
C48/80 0.0 0.0 0.0 0.0
C48/80 + LPS 24h 15±3.0‡‡ 20±2.0‡‡ 13±2.2‡‡ 16±1.5‡‡‡
        Data are the mean±SEM of neutrophils (Nϕ) and mononuclear phagocytes (Mϕ) per mm2 analyzed in the ocular tissues of control
        animals, animals with EIU at the initial (LPS 24h) and late phases (LPS 48h), animals pretreated with c48/80 and animals
        pretreated with c48/80 and then subjected to endotoxemia (c48/80 + LPS24h). ***p<0.001 versus control, †††p<0.001 versus
        LPS 24h; ‡‡p<0.01, or ‡‡‡p<0.001 versus C48/80.
TABLE 3. QUANTITATIVE ANALYSIS OF NEUTROPHILS AND MONONUCLEAR PHAGOCYTIC CELLS IN THE POSTERIOR EYE SEGMENT.
Groups Choroid Retina
  Nϕ Mϕ Nϕ Mϕ
Control 0.0 0.0 0.0 0.0
LPS 24h 85±7.0*** 0.0 45±3.0** 0.0
LPS 48h 15±3.0††† 7.2±2.0† 32±4.0† 3.7±2.2
C48/80 0.0 0.0 0.0 0.0
C48/80 + LPS 24h 12±3.0‡‡ 0.0 14±2.5‡‡ 0.0
        Data are the mean±SEM of neutrophils (Nϕ) and mononuclear phagocytes (Mϕ) per mm2 analyzed in the ocular tissues of control
        animals, animals with EIU at the initial (LPS 24h) and late phases (LPS 48h), pretreated with c48/80, and animals pretreated
        with c48/80 and then subjected to endotoxemia (c48/80 + LPS24h). **p<0.01 or ***p<0.001 versus control, †p<0.05 or
        †††p<0.001 versus LPS 24h; ‡‡p<0.01 versus C48/80.
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histamine  from  degranulated  mast  cells  plays  a  role  in
vasodilatation,  increased  vascular  permeability,  interstitial
edema and in the expression of P-selectin on the membrane
Figure  2.  Cellular  and  protein
extravasations into the AqH during EIU.
A: Quantitative analysis of neutrophils
(Nϕ) and mononuclear phagocytic cells
(Mϕ)  in  the  AqH.  The  results  are
expressed as number of cells per 103/μl.
***p<0.001 versus control; †††p<0.001
versus LPS 24 h. B: The total protein
concentration  in  the  AqH  are
demonstrated  in  mg  of  protein/ml.
***p<0.001 versus control, †††p<0.001
versus  LPS  24  h,  ‡‡p<0.01  versus
c48/80. C: Annexin A1 protein content
was analyzed by western blotting and
detected by the primary antibody rabbit
anti-Anxa1. Two bands of 37 kDa and
33  kDa  molecular  weights  were  seen
corresponding,  to  intact  protein  and
NH2-terminal  cleaved  protein,
respectively.  The  55  kDa  molecular
weight tubulin-α was used as control.
Control animals, animals at the initial
(LPS 24 h) and late phase (LPS 48 h) of
the  inflammatory  process,  animals
pretreated  c48/80  (c48/80)  only,  or
pretreated  with  c48/80  before  EIU
(c48/80  +  LPS  24h).  n=10  animals/
group.
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1315of endothelial cells, which then contributes to the recruitment
of  leukocytes  [42].  Following  with  this  hypothesis,  a
significant  reduction  occurred  in  the  recruitment  and
migration of leukocytes and in the levels of plasma proteins
in both AqH and ocular tissues in animals pre-treated with
c48/80 before the induction of uveitis. For the same reasons,
we  wish  to  propose  that  the  absence  of  pharmacological
mediators from mast cells decreased vascular permeability,
reducing  leukocyte  chemotaxis  and  proteins  in  the  AqH.
Previous studies performed in our laboratory showed that the
preferential  location  of  mast  cells  is  in  the  anterior  eye
segment of birds, which indicates that the pharmacological
mediators released from their cytoplasmatic granules may act
physiologically in the AqH flow [43]. Moreover, our results
suggest that after c48/80 treatment there was an increase in
the level of Anxa1 in the AqH, and these data provide indirect
confirmation that pro-and anti-inflammatory mediators are
released from mast cells into the aqueous humor.
Because several lines of experimental evidence indicate
the anti-inflammatory role of this protein [24] we examined
Anxa1  expression  in  inflammatory  cells  (mast  cells,
neutrophils,  and  mononuclear  phagocytes)  during  EIU.
Anxa1 expression was different in the control and inflamed
ocular tissues. At 24 h after LPS administration, a time period
at which mast cells already showed signs of degranulation,
mast cells expressed low amounts of Anxa1. Lower levels of
Anxa1 were also found in nasal poliposis degranulated mast
cells  [44].  However,  the  first  report  of  the  presence  of
endogenous Anxa1 in mast cells [45] showed an increased
concentration of the protein in the CTMCs of rat mesenteries
after  experimental  inflammation  and  demonstrated  its
regulation  after  administration  of  the  glucocorticoid
dexamethasone. These findings indicate that these cells are a
potential source of Anxa1 during the inflammatory process.
In this regard, our results suggest that the release of mediators
from mast cells during endotoxemia, including Anxa1, could
act to inhibit the synthesis of pro-inflammatory mediators
such as phospholipase A2, prostaglandin D2, and leukotriene
E2 and stimulates the production of factors that contribute to
the resolution of inflammation [24,46,47].
Finally,  Anxa1  expression  was  also  evaluated  in
leukocytes during inflammation. These investigations showed
that neutrophils and mononuclear phagocytic cells expressed
endogenous Anxa1 at 24 h, with a significant increase after
48 h. Our results indicated that the increase of endogenous
Anxa1  expression  in  cells  that  had  transmigrated  to  the
inflammatory sites reduced the activation of these leukocytes,
contributing to the resolution of inflammation, as shown in
other studies [24,48]. Furthermore, the immunohistochemical
and  in  situ  hybridization  studies  demonstrated  that  the
endogenous  Anxa1  expression  increased  in  the  plasma
membrane of circulating neutrophils during the inflammatory
process and also in the cell cytoplasm of those cells after the
transmigration  [26].  These  data  indicated  that  Anxa1was
regulated during leukocyte transmigration. In addition, other
investigations  have  shown  that  the  inflammatory  process
Figure 3. Anxa1 protein expression in
inflammatory  cells  in  EIU.
Immunohistochemistry was performed
to visualize the protein in (A) mast cells
(open  arrow)  and  (B)  neutrophils
(arrows) in the ciliary body at 24 h after
EIU and (C) mononuclear phagocytic
cells (arrowheads) adhered to the iris
surface  at  48  h  after  EIU.  V:  blood
vessel.  Counterstained  with
hematoxylin.  Bars,  10  μm.  D:
Semiquantitative  Anxa1  densitometric
analysis. Data are the mean±SEM of the
densitometric  index  (n=5  animals/
group). *p<0.05 versus control group;
†p<0.05 versus LPS 24 h. Neutrophils
(Nϕ) and mononuclear phagocytic cells
(Mϕ). ND, not detected.
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1316induced by zymozan exacerbated leukocyte transmigration
into the peritoneal cavity in the absence of the Anxa1 protein,
in Anxa1 knockout animals [49].
Regarding the role of Anxa1 in phagocytic mononuclear
cells,  the  absence  of  the  endogenous  protein  inhibited
phagocytosis  in  40%  of  the  apoptotic  polymorphonuclear
cells [50]. Several studies have indicated the involvement of
Anxa1 in the regulation of apoptosis in inflammatory cells,
because its overexpression in monocytes increased apoptosis
[51,52]. In addition, this protein has been implicated as a
marker of cells undergoing apoptosis, possibly acting as an
endogenous  ligand  for  phosphatidylserine,  facilitating  the
recognition, ingestion and, consequently, the removal of these
cells by macrophages [53,54]. Based on these investigations
and our observations of the increased expression of Anxa1 in
neutrophils and phagocytic mononuclear cells during the late
phase of inflammation, it is tempting to indicate that Anxa1
could also contribute to the resolution of the inflammatory
process. However, further investigations are required for a
better understanding of this issue.
Conclusions: Based on the experimental model of uveitis,
our results indicated that mast cells are a potential source of
pharmacological mediators, that are strongly related to the
pathophysiology of EIU, and that the endogenous protein
Anxa1  is  a  key  mediator  in  the  homeostasis  of  the
inflammatory process, showing regulatory action in leukocyte
diapedesis. Thus, Anxa1 may be an innovative form of therapy
for uveitis, by preventing the activation of mast cells and/or
the infiltration of leukocytes in ocular tissues.
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